Skip to content
value.today

FOG Pharmaceuticals, Inc.

🇺🇸 Boston, Massachusetts, USAPharmaceuticalsFounded 2015
Total raised
$278 M
4 rounds on record
Latest round
$178 M
Nov 2022
First round on record
May 2016
Today
Went public
See the company page

FOG Pharmaceuticals, Inc. is listed today as Parabilis Medicines, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of FOG Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2022$178 MNo. 4$50 to $250 million

FOG Pharmaceuticals, Inc.: Raise no. 4, Nov 2022

Investors in this round

24 investors had bought by the notice of Dec 2, 2022: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for FOG Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$178 M of $178 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory L. Verdine · Executive Officer, Director
  • WeiQing M. Zhou · Executive Officer
  • Barbara M. Weber · Director
  • Corey S. Goodman · Director
  • Edward M. Fitzgerald · Director
  • Jeffrey A. Leerink · Director
  • Krishna M. Yeshwant · Director
  • Rick M. Klausner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gregory L. Verdine, President. Source: SEC Form D, newest notice filed Dec 2, 2022. Read the notice at the SEC.

equitySEC
Dec 2020$23 MNo. 3$10 to $50 million

FOG Pharmaceuticals, Inc.: Raise no. 3, Dec 2020

Investors in this round

22 investors had bought by the notice of Jan 5, 2021: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for FOG Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$23 M of $107 M offered; $84 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory L. Verdine · Executive Officer, Director
  • WeiQing M. Zhou · Executive Officer
  • Barbara M. Weber · Director
  • Edward M. Fitzgerald · Director
  • Jeffrey A. Leerink · Director
  • Krishna M. Yeshwant · Director
  • Leon M. Chen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gregory L. Verdine, President. Source: SEC Form D, newest notice filed Jan 5, 2021. Read the notice at the SEC.

equitySEC
Feb 2018$66 MNo. 2$50 to $250 million

FOG Pharmaceuticals, Inc.: Raise no. 2, Feb 2018

Investors in this round

24 investors had bought by the notice of May 16, 2018: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for FOG Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$66 M of $66 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory L. Verdine · Executive Officer, Director
  • WeiQing A. Zhou · Executive Officer
  • Edward A. Fitzgerald · Director
  • Jeffrey A. Leerink · Director
  • Leon A. Chen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gregory L. Verdine, President. Source: SEC Form D and 1 amendment, newest notice filed May 16, 2018. Read the notice at the SEC.

equitySEC
May 2016$11 MNo. 1$10 to $50 million

FOG Pharmaceuticals, Inc.: Raise no. 1, May 2016

Investors in this round

13 investors had bought by the notice of Aug 22, 2017: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for FOG Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,100,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory L Verdine · Executive Officer, Director
  • WeiQing A Zhou · Executive Officer
  • Edward M Fitzgerald · Director
  • Jeffrey A Leerink · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gregory L. Verdine, President. Source: SEC Form D and 1 amendment, newest notice filed Aug 22, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • FOG Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2022).

    SEC Form D · Dec 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2022

That is all the official record says: FOG Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of FOG Pharmaceuticals, Inc. are on record.

Investors#

15 named in official filings. Open an investor to see everything it has backed.

Investors in FOG Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Alexis BorisyPersonnot statednot statedHeld Series F preferred stock, director (Form 3, 2026)SEC Form 3
Deerfield Healthcare Innovations Fund, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Deerfield Mgmt HIF, L.PFund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Edward M. FitzgeraldPersonnot statednot statedHeld Series B, C and F preferred stock, director (Form 3, 2026)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series E and F preferred stock, director (Form 3, 2026)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series E and F preferred stock, director (Form 3, 2026)SEC Form 3
RA Capital Nexus Fund III, L.P.Fund or asset managernot statednot statedHeld Series E and F preferred stock, director (Form 3, 2026)SEC Form 3
Soleus Capital Management, L.P.Fund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Soleus GP, LLCOthernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Soleus PE GP III, LLCOthernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Soleus Private Equity Fund III, L.P.Private equitynot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2026)SEC Form 3
Soleus Private Equity GP III, LLCPrivate equitynot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2026)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 24 investors.

Largest shareholders today

Institutions holding Parabilis Medicines, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by FOG Pharmaceuticals, Inc.
NameRoleNamed in
Gregory L. VerdineExecutive officerDec 2022
WeiQing M. ZhouExecutive officerDec 2022
WeiQing A. ZhouExecutive officerMay 2018
Gregory L VerdineExecutive officerAug 2017
WeiQing A ZhouExecutive officerAug 2017
Michael L AcetiExecutive officerJun 2016
WeiQing L ZhouExecutive officerJun 2016
Barbara M. WeberDirectorDec 2022
Corey S. GoodmanDirectorDec 2022
Edward M. FitzgeraldDirectorDec 2022
Gregory L. VerdineDirectorDec 2022
Jeffrey A. LeerinkDirectorDec 2022
Krishna M. YeshwantDirectorDec 2022
Rick M. KlausnerDirectorDec 2022
Leon M. ChenDirectorJan 2021
Edward A. FitzgeraldDirectorMay 2018
Leon A. ChenDirectorMay 2018
Edward M FitzgeraldDirectorAug 2017
Gregory L VerdineDirectorAug 2017
Jeffrey A LeerinkDirectorAug 2017

Went public since 2026. Its SEC number is that of a company listed on a stock exchange.